Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2117
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSANTOS-OLIVEIRA, Joanna R.-
dc.contributor.authorREGIS, Eduardo G.-
dc.contributor.authorGIACOIA-GRIPP, Carmem B. W.-
dc.contributor.authorVALVERDE, Joanna G.-
dc.contributor.authorALEXANDRINO-DE-OLIVEIRA, Priscilla-
dc.contributor.authorLINDOSO, Jose Angelo L.-
dc.contributor.authorGOTO, Hiro-
dc.contributor.authorOLIVEIRA-NETO, Manoel P.-
dc.contributor.authorGUERRA, Jorge O.-
dc.contributor.authorGRINSZTEJN, Beatriz-
dc.contributor.authorJERONIMO, Selma B.-
dc.contributor.authorMORGADO, Mariza G.-
dc.contributor.authorDA-CRUZ, Alda M.-
dc.date.accessioned2013-09-23T16:43:50Z-
dc.date.available2013-09-23T16:43:50Z-
dc.date.issued2013-
dc.identifier.citationJOURNAL OF INFECTIOUS DISEASES, v.208, n.1, p.57-66, 2013-
dc.identifier.issn0022-1899-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2117-
dc.description.abstractBackground. Leishmania infection is a cofactor in the heightened cellular activation observed in patients with American visceral leishmaniasis and human immunodeficiency virus type 1 (HIV) infection, with or without progression to AIDS (AVL/HIV). Thus, the persistence of a high parasite load despite antileishmanial therapy could be responsible for the continued immune stimulation. Methods. CD8(+) T cells expressing CD38, parasite load, lipopolysaccharide (LPS), soluble CD14, macrophage migration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proinflammatory cytokines (interleukin 1 beta, interleukin 6, interleukin 8, interleukin 17, interferon gamma, and tumor necrosis factor) were measured in 17 patients with AVL/HIV, 16 with HIV, and 14 healthy subjects (HS). Results. Lower Leishmania parasitemia was observed after antileishmanial and antiretroviral therapies. However, higher levels of CD38(+) on CD8(+) T cells were observed in both clinical phases of leishmaniasis, compared with HIV cases. AVL/HIV and HIV patients showed higher levels of LPS and IFABP than HS. Proinflammatory cytokine levels were significantly augmented in patients with active coinfection, as well as those with remission of Leishmania infection. LPS levels and Leishmania infection were positively correlated with CD38 expression on CD8(+) T cells and with IL-6 and IL-8 levels. Conclusions. LPS levels along with the immune consequences of Leishmania infection were associated with elevated cellular activation in coinfected patients. As a consequence, secondary chemoprophylaxis for leishmaniasis or even the use of antiinflammatory drugs or antibiotics may be considered for improving the prognosis of AVL/HIV.-
dc.description.sponsorshipPrograma Nacional de DST/AIDS, Ministerio da Saude [ED00095/2007]-
dc.description.sponsorshipInstituto Oswaldo Cruz-
dc.description.sponsorshipFAPERJ [FAPERJ nota 10]-
dc.description.sponsorshipCNPq-
dc.language.isoeng-
dc.publisherOXFORD UNIV PRESS INC-
dc.relation.ispartofJournal of Infectious Diseases-
dc.rightsrestrictedAccess-
dc.subjectvisceral leishmaniasis-HIV/AIDS coinfection-
dc.subjectmicrobial translocation-
dc.subjectinflammatory cytokines-
dc.subject.othert-cells-
dc.subject.otherimmune activation-
dc.subject.othergastrointestinal-tract-
dc.subject.otherinfected patients-
dc.subject.otherkala-azar-
dc.subject.otherdisease-
dc.subject.othervirus-
dc.subject.othercytokines-
dc.subject.otheraids-
dc.subject.otherreplication-
dc.titleMicrobial Translocation Induces an Intense Proinflammatory Response in PatientsWith Visceral Leishmaniasis and HIV Type 1 Coinfection-
dc.typearticle-
dc.rights.holderCopyright OXFORD UNIV PRESS INC-
dc.identifier.doi10.1093/infdis/jit135-
dc.identifier.pmid23539743-
dc.subject.wosImmunology-
dc.subject.wosInfectious Diseases-
dc.subject.wosMicrobiology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSANTOS-OLIVEIRA, Joanna R.:Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalREGIS, Eduardo G.:Fiocruz MS, Inst Oswaldo Cruz, Lab Pesquisa Timo, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalGIACOIA-GRIPP, Carmem B. W.:Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalVALVERDE, Joanna G.:Univ Fed Rio Grande do Norte, Dept Bioquim, BR-59072970 Natal, RN, Brazil-
hcfmusp.author.externalALEXANDRINO-DE-OLIVEIRA, Priscilla:Univ Fed Mato Grosso do Sul, Univ Hosp, Hosp Dia Profa Esterina Corsini, Campo Grande, Brazil-
hcfmusp.author.externalOLIVEIRA-NETO, Manoel P.:Fiocruz MS, IPEC, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalGUERRA, Jorge O.:Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil-
hcfmusp.author.externalGRINSZTEJN, Beatriz:Fiocruz MS, IPEC, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalJERONIMO, Selma B.:Univ Fed Rio Grande do Norte, Dept Bioquim, BR-59072970 Natal, RN, Brazil-
hcfmusp.author.externalMORGADO, Mariza G.:Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil-
hcfmusp.author.externalDA-CRUZ, Alda M.:Fiocruz MS, Inst Oswaldo Cruz, Lab Interdisciplinar Pesquisas Med, BR-21045900 Rio De Janeiro, RJ, Brazil; Univ Estado Rio de Janeiro, Fac Ciencias Med, Disciplina Parasitol, Rio De Janeiro, Brazil-
hcfmusp.description.beginpage57-
hcfmusp.description.endpage66-
hcfmusp.description.issue1-
hcfmusp.description.volume208-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84878611218-
hcfmusp.origem.idWOS:000319830300010-
hcfmusp.publisher.cityCARY-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAlexandrino-de-Oliveira P, 2010, MEM I OSWALDO CRUZ, V105, P692, DOI 10.1590/S0074-02762010000500016-
hcfmusp.relation.referenceAlexandrino-de-Oliveira P, 2010, BMC INFECT DIS, V10, P35863-
hcfmusp.relation.referenceAlvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07-
hcfmusp.relation.referenceAntinori S, 2007, CLIN INFECT DIS, V44, P1602, DOI 10.1086/518167-
hcfmusp.relation.referenceAppay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276-
hcfmusp.relation.referenceBalkhair A, 2008, INT J INFECT DIS, V12, P111, DOI 10.1016/j.ijid.2007.04.009-
hcfmusp.relation.referenceBarreto-De-Souza V, 2006, J INFECT DIS, V194, P846, DOI 10.1086/506618-
hcfmusp.relation.referenceBernier R, 1998, J IMMUNOL, V160, P2881-
hcfmusp.relation.referenceBrasil Ministerio da Saude Departamento de DST Aids e hepatites virais, PROT CLIN DIR TER AD-
hcfmusp.relation.referenceBrasil Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia Epidemiologica, 2006, MAN VIG CONTR LEISHM-
hcfmusp.relation.referenceBrenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001-
hcfmusp.relation.referenceBrenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874-
hcfmusp.relation.referenceBrenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511-
hcfmusp.relation.referenceCalandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200-
hcfmusp.relation.referenceCaradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1179/096805100101532063-
hcfmusp.relation.referenceCasado JL, 2001, EUR J CLIN MICROBIOL, V20, P202, DOI 10.1007/s10096-001-8082-z-
hcfmusp.relation.referenceConnolly NC, 2005, AIDS REV, V7, P168-
hcfmusp.relation.referenceCooke KR, 2002, J ENDOTOXIN RES, V8, P441, DOI 10.1179/096805102125001046-
hcfmusp.relation.referenceCota GF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001153-
hcfmusp.relation.referenceDoisne JM, 2004, J IMMUNOL, V173, P2410-
hcfmusp.relation.referenceDouek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549-
hcfmusp.relation.referenceEstes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052-
hcfmusp.relation.referenceGiorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660-
hcfmusp.relation.referenceGonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09-
hcfmusp.relation.referenceGoto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002-
hcfmusp.relation.referenceHicks L, 2009, EUR J GASTROEN HEPAT, V21, P117, DOI 10.1097/MEG.0b013e32830e6fdb-
hcfmusp.relation.referenceRodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010-
hcfmusp.relation.referenceLee PI, 2009, J INFECT DIS, V199, P1664, DOI 10.1086/598953-
hcfmusp.relation.referenceLieberman JM, 1997, SURGERY, V121, P335, DOI 10.1016/S0039-6060(97)90363-9-
hcfmusp.relation.referenceLiu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83-
hcfmusp.relation.referenceBaba Chalamalasetty Sreenivasa, 2006, Indian J Gastroenterol, V25, P309-
hcfmusp.relation.referenceMcCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1-
hcfmusp.relation.referenceMedrano FJ, 1998, CLIN EXP IMMUNOL, V114, P403, DOI 10.1046/j.1365-2249.1998.00733.x-
hcfmusp.relation.referenceMehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196-
hcfmusp.relation.referenceMiller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068-
hcfmusp.relation.referenceMock DJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002635-
hcfmusp.relation.referenceNazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852-
hcfmusp.relation.referenceRabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507-
hcfmusp.relation.referenceSaha S, 2006, INDIAN J MED RES, V123, P245-
hcfmusp.relation.referenceSandler NG, 2011, GASTROENTEROLOGY, V141, P1220, DOI 10.1053/j.gastro.2011.06.063-
hcfmusp.relation.referenceSantos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198-
hcfmusp.relation.referenceSenent SG, 2009, GASTROENTEROL HEPATO, V32, P176, DOI 10.1016/j.gastrohep.2008.09.021-
hcfmusp.relation.referencePeruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x-
hcfmusp.relation.referenceSinha PK, 2006, INDIAN J MED RES, V123, P197-
hcfmusp.relation.referenceSousa-Gomes ML, 2011, EPIDEMIOL SERV SAUDE, V20, P519-
hcfmusp.relation.referenceWeirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11-
hcfmusp.relation.referenceWolday D, 1998, SCAND J INFECT DIS, V30, P29-
hcfmusp.relation.referenceZhao CQ, 2004, CLIN IMMUNOL, V113, P81, DOI 10.1016/j.clim.2004.06.003-
hcfmusp.relation.referenceNylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPERJ-
hcfmusp.remissive.sponsorshipMinistério da Saúde-
hcfmusp.citation.scopus32-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPR
Departamento de Medicina Preventiva - FM/MPR

Artigos e Materiais de Revistas Científicas - LIM/38
LIM/38 - Laboratório de Epidemiologia e Imunobiologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_LINDOSO_Microbial_Translocation_Induces_an_Intense_Proinflammatory_Response_in_2013.PDF
  Restricted Access
publishedVersion (English)1.09 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.